JANUS LIVING INC CL-A-1

JAN · NYSE

Updated at 2026-11-16 23:17:51

$32.10+0.87%
Today's High
$32.59
Today’s Low
$31.84
JANUS LIVING INC CL-A-1 (JAN) Stock Price & Market Data
Search empty state illustration
...

Candlestick trends are for reference. Refer to the trading page for actual data.

Key Statistics

Previous Open
$32.32
Previous Close
$31.82
Volume
2.22M
Market Cap
$10.84B
P/E Ratio
223.97X
EPS
$0.22

Previous Day Range

$31.55$32.53

52-Week Range

$22.76$32.99

Company Overview

Sector
REAL ESTATE
Industry
Real Estate
Sub-industry
REIT - RESIDENTIAL
Headquarters
4600 SOUTH SYRACUSE STREET, DENVER, CO, UNITED STATES, 80237
Country
US
Listing Date
2026-03-20
Fiscal Year End
December
Shares Outstanding
234.37M
CIK
0002100805

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for pain management. The company is headquartered in Las Vegas, Nevada.

Financial Metrics

Revenue

2026-09-30

$268.3M

2026-06-30

$216.45M

2026-03-31

$200.34M

2025-12-31

$322.92M

Operating Expenses

2026-09-30

-$69.97M

2026-06-30

-$48.38M

2026-03-31

-$48.11M

2025-12-31

$425.7M

Net Income

2026-09-30

-$4.32M

2026-06-30

$10.72M

2026-03-31

$31.33M

2025-12-31

-$57.83M

Net Profit Margin

2026-09-30

-1.61%

2026-06-30

4.95%

2026-03-31

15.63%

2025-12-31

-17.9%

Earnings Per Share

2026-09-30

$0.25

2026-06-30

$0.24

2026-03-31

$0.01

2025-12-31

--

Earnings Before Interest, Taxes, Depreciation, and Amortization

2026-09-30

$74.45M

2026-06-30

$69.93M

2026-03-31

$80.74M

2025-12-31

$114.48M

Effective Tax Rate

2026-09-30

-18.88%

2026-06-30

13.31%

2026-03-31

3.86%

2025-12-31

-16.5%

FAQs

Risk Warning

Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.